VIR BIOTECHNOLOGY INC (VIR)

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting

Noteworthy Friday Option Activity: GSAT, VIR, INTC

Top movers in Friday's session

Intrigued by the market activity in the middle of the day on Friday? Uncover the key winners and losers of today's session in our insightful analysis.

Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Vir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024

Vir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024

Vir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference

Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer

Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END

Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031

Vir Biotechnology Becomes Oversold (VIR)

Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024

VIR stock results show that Vir Biotechnology missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

VIR Stock Earnings: Vir Biotechnology Misses EPS, Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Vir Biotechnology (NASDAQ:VIR) just reported results for the second quarter of ...

Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities

Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers

Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark

On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.

Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

3 Undervalued Biotech Gems With 200%+ Analyst Price Targets

These three undervalued biotech stocks have begun garnering investor attention as their treatments show promise.

Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Notable Two Hundred Day Moving Average Cross - VIR

Tobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of Treatment

Vir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Vir Biotechnology Appoints Mark Eisner, M.D., M.P.H. as Chief Medical Officer

Vir Biotechnology to Host 2024 Annual Meeting of Stockholders

Multiple Abstracts Highlighting Vir Biotechnology’s Latest Hepatitis Delta & B Data Accepted for Presentation at the EASL Congress 2024

Vir Biotechnology Announces SOLSTICE Data to be Featured as an Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2024

Brii Biosciences Announces Two Breakthrough Therapy Designations for BRII-877 and BRII-835 Building on Extensive Clinical Evidence from Multiple Phase 2 Studies

/PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient...

VIR Crosses Above Key Moving Average Level